Recursion to Participate in Upcoming Investor Conferences Feb 23, 2026 07:55AM
Which healthcare stocks are at risk from AI and which to buy Feb 14, 2026 10:00AM
KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX) Nov 20, 2024 03:13PM
KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX ) Oct 2, 2024 02:17PM
KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX ) Sep 3, 2024 03:00PM


Jun 26, 2024 08:59AM KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )
Mar 1, 2024 07:59AM Recursion to Participate in Upcoming Investor Conferences
Aug 1, 2023 08:30AM Recursion to Participate in Upcoming Investor Conference
Mar 1, 2023 08:00AM Recursion to Participate in Upcoming Investor Conferences
Mar 1, 2023 08:00AM Recursion to Participate in Upcoming Investor Conferences
Oct 25, 2022 08:05AM Recursion Pharmaceuticals (RXRX) Announces $150M Private Placement at $9.80/sh
Oct 25, 2022 08:00AM Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
Aug 2, 2022 07:55AM Recursion to Participate in Upcoming Investor Conference
Mar 2, 2022 08:47AM Recursion to Participate in Upcoming Investor Conferences
May 11, 2021 04:55AM UPDATE: KeyBanc Starts Recursion Pharmaceuticals (RXRX) at Overweight
Apr 21, 2021 08:00AM Recursion Pharmaceuticals Announces Closing of Initial Public Offering
Apr 16, 2021 12:44PM Recursion Pharmaceuticals Inc. (RXRX) IPO Opens 67% Higher
Apr 16, 2021 05:53AM Recursion Pharmaceuticals Inc. (RXRX) Prices 24.24M Share IPO at $18/Sh
Apr 16, 2021 12:13AM Recursion Pharmaceuticals Announces Pricing of Initial Public Offering